What is the current short‑interest and institutional ownership trend post‑release? | ACLX (Aug 07, 2025) | Candlesense
ACLX

What is the current short‑interest and institutional ownership trend post‑release?

Short‑interest and institutional‑ownership data are not included in the press release you provided.

The Business Wire announcement about Arcellx’s Q2 2025 results focuses on clinical trial enrollment, revenue, expenses, and other operating metrics, but it does not disclose:

Metric Mentioned in the release?
Current short‑interest (shares short / % of float) ❌
Recent change in short‑interest (increase/decrease vs. prior period) ❌
Institutional ownership % (overall or by major holders) ❌
Trend in institutional ownership (e.g., new buy‑ins, sell‑offs) ❌

Because the release lacks those figures, any answer about the “current short‑interest and institutional‑ownership trend post‑release” would have to be based on external market data rather than the content you supplied.

How to obtain the information you need

Below is a step‑by‑step guide to retrieve the most up‑to‑date short‑interest and institutional‑ownership metrics for Arcellx, Inc. (NASDAQ: ACLX):

1. Short‑interest

Source What you’ll find How to locate it
NASDAQ website (nasdaq.com/market-activity/stocks/aclx/short-interest) Shares short, short‑interest % of float, days‑to‑cover, historical short‑interest data (usually reported bi‑weekly) Search “ACLX short interest” on Nasdaq’s market activity page.
FINRA Short Sale Reporting (finra.org) Detailed short‑sale reports for the most recent reporting period (usually the last two weeks) Use the “Short Sale Data” tool, filter by ticker “ACLX”.
Financial data platforms (Bloomberg, FactSet, S&P Capital IQ, Refinitiv) Real‑time or near‑real‑time short‑interest, trend charts, percent change vs. prior period Enter the ticker and look for the “Short Interest” tab.
Yahoo! Finance / MarketWatch Summary short‑interest % of float and recent change (often a 5‑day or 30‑day change) Search “ACLX” → “Statistics” → scroll to “Share Statistics”.

What to look for after the Q2 release (post‑August 7, 2025):

- Short‑interest level (e.g., 2.1 M shares short, representing 12 % of the float).

- Change vs. prior reporting period (e.g., “down 5 % week‑over‑week”).

- Days‑to‑cover (short‑interest divided by average daily volume).

- Any notable spikes that often accompany earnings releases (investors may short after a miss or increase short positions if they expect volatility).

2. Institutional ownership

Source What you’ll find How to locate it
NASDAQ Institutional Holdings (nasdaq.com/market-activity/stocks/aclx/institutional-holdings) List of top institutional holders, % of shares owned, changes in holdings over the last 13‑F filing (quarterly) Search “ACLX institutional holdings”.
SEC Form 13F filings (sec.gov/edgar/search) Detailed quarterly holdings of each institutional manager that files a 13F; can compute net change in ownership. Pull the most recent 13F for the quarter ending June 30 2025 (or the next filing, typically early August).
Morningstar / Bloomberg Aggregate institutional ownership % (e.g., 68 % of float) and trend (e.g., “up 2 % over the past month”). Use the “Ownership” tab for the ticker.
FactSet Ownership Summary Institutional ownership breakdown by category (mutual funds, pension funds, hedge funds, etc.) and net inflows/outflows. Look under “Ownership” > “Institutional”.
Yahoo! Finance / MarketWatch Summary % owned by institutions, top 10 holders, and change since previous quarter. Search “ACLX” → “Holders”.

What to watch for after the earnings release:

- Net change in institutional ownership (e.g., “institutions added 1.5 % of the float in the week following the earnings release”).

- Shift in holder type (e.g., hedge funds increasing positions while mutual funds remain flat).

- New large investors entering or exiting (often reported in 13F or news commentary).

- Comparison to prior quarters to assess whether the earnings beat/miss is prompting a broader re‑allocation.

3. Putting the pieces together

Once you have the raw numbers, you can describe the trend:

Metric Recent level Change vs. prior period Interpretation
Short‑interest (shares) e.g., 2.0 M –5 % week‑over‑week Short sellers are reducing positions, possibly reflecting confidence in the Q2 results.
Short‑interest (% of float) e.g., 11 % –0.5 pp (percentage points) A modest decline; still a notable short interest.
Days‑to‑cover e.g., 3.2 –0.3 Easier for shorts to cover if needed.
Institutional ownership (overall) e.g., 70 % +1 % vs. Q1 Institutions are modestly increasing exposure, perhaps betting on the positive trial data.
Top institutional net change e.g., Vanguard +0.4 %, BlackRock +0.3 % – Indicates major managers are buying.
Hedge‑fund net change e.g., Citadel –0.2 % – Some speculative investors may be trimming.

Typical narrative:

- If short‑interest falls while institutional ownership rises, the market sentiment is generally bullish post‑release.

- Conversely, a rise in short‑interest coupled with a decline in institutional holdings would suggest bearish sentiment.

Action plan for you

  1. Gather the latest short‑interest data (Nasdaq or Bloomberg) for ACLX as of the most recent reporting date (likely the week of August 7‑14, 2025).
  2. Pull the latest institutional‑ownership figures (Nasdaq “Institutional Holdings” page or the most recent 13F filings).
  3. Calculate week‑over‑week (or month‑over‑month) changes to identify the direction of the trend.
  4. Compare against the Q2 results (e.g., if the iMMagine‑1 data were better than expected, a decrease in short‑interest and increase in institutional ownership would be consistent).
  5. Summarize using a table or bullet points, highlighting any notable large‑holder moves.

Bottom line

  • The press release you provided does not contain short‑interest or institutional‑ownership data.
  • To answer the question, you’ll need to consult market‑data sources (Nasdaq, FINRA, Bloomberg, FactSet, SEC 13F filings, etc.) and then evaluate the changes relative to the previous reporting periods.
  • Once you have those numbers, you can articulate whether short‑interest is rising or falling and whether institutional investors are increasing or decreasing their stakes in Arcellx after the Q2 2025 earnings release.

If you retrieve the specific figures and share them here, I can help you interpret the trend in detail.

Other Questions About This News

What were the revenue, net loss, and cash burn figures for the quarter, and how do they compare to the same quarter last year? What is the projected timeline for commercialization if the trial succeeds, and how does that affect peak revenue projections? Are there any upcoming catalysts (e.g., data readouts, conference presentations) that could drive short‑term volatility? When is the regulatory filing timeline for the 'iMMagine-1' study data and potential FDA submission? What are the implications of the 117‑patient data on the potential market size and pricing model for anito‑cel? How did Arcellx's Q2 2025 earnings compare to analyst expectations and consensus forecasts? What is the outlook for cash runway and upcoming financing needs? How does the enrollment and data from the 117‑patient registrational study impact the valuation of anito‑cel? How does the current valuation (P/E, EV/EBITDA) compare to other cell‑therapy companies such as CRISPR Therapeutics, CAR-T makers, etc.? Are there any changes in the management team or board that could affect strategy execution? How does the sentiment score of 40 translate into market sentiment or analyst revisions? What are the key risks highlighted in the 10‑Q filing and how might they affect the risk‑adjusted return? How does the current share price compare to historical averages and the company's current market cap? What are the prospects and timelines for any upcoming partnership or licensing deals?